Compare Hims and Hers Health Inc (HIMS) vs D Wave Quantum Inc (QBTS) Price & Performance

Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.

The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.

D-Wave Quantum (QBTS) trades at $14.42, down 5.26% today, amid bearish technical signals and ongoing legal investigations. The company shows severe financial stress with a -2,001.59% net income margin and -$355M net loss in 2025, though it maintains a 64.19% gross margin. Revenue declined from $25M to $12M year-over-year, while cash flow turned negative in 2026. Despite 100% analyst buy ratings with a $34.38 consensus target, multiple law firms are investigating potential securities law violations.

The stock faces significant fundamental challenges with massive losses and declining revenue, offset by strong analyst optimism about quantum computing potential. Key risks include ongoing legal probes, cash burn acceleration, and competitive pressures in the emerging quantum sector. The current price sits 58% below analyst targets, creating potential upside if execution improves, but substantial operational turnaround is needed.